American Century Companies Inc. lowered its holdings in shares of Nevro Corp. (NYSE:NVRO) by 90.8% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 53,776 shares of the medical equipment provider’s stock after selling 533,659 shares during the quarter. American Century Companies Inc. owned 0.18% of Nevro Corp. worth $4,887,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also bought and sold shares of the company. Teachers Advisors LLC lifted its holdings in shares of Nevro Corp. by 2.0% in the 1st quarter. Teachers Advisors LLC now owns 43,608 shares of the medical equipment provider’s stock worth $4,086,000 after buying an additional 873 shares during the period. Legal & General Group Plc lifted its holdings in shares of Nevro Corp. by 5.4% in the 1st quarter. Legal & General Group Plc now owns 8,137 shares of the medical equipment provider’s stock worth $760,000 after buying an additional 418 shares during the period. Schwab Charles Investment Management Inc. lifted its holdings in shares of Nevro Corp. by 11.0% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 94,705 shares of the medical equipment provider’s stock worth $8,874,000 after buying an additional 9,405 shares during the period. State Street Corp lifted its stake in shares of Nevro Corp. by 4.9% during the 1st quarter. State Street Corp now owns 461,309 shares of the medical equipment provider’s stock worth $43,222,000 after purchasing an additional 21,558 shares during the last quarter. Finally, Bank of Montreal Can lifted its stake in shares of Nevro Corp. by 36.6% during the 2nd quarter. Bank of Montreal Can now owns 13,187 shares of the medical equipment provider’s stock worth $982,000 after purchasing an additional 3,534 shares during the last quarter.
A number of equities research analysts recently weighed in on the company. Morgan Stanley upped their price objective on Nevro Corp. from $87.00 to $95.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 8th. Northland Securities restated a “buy” rating and set a $96.00 price objective on shares of Nevro Corp. in a research note on Tuesday, August 8th. BidaskClub cut Nevro Corp. from a “hold” rating to a “sell” rating in a research note on Saturday, October 28th. TheStreet upgraded Nevro Corp. from a “d+” rating to a “c-” rating in a research note on Monday, November 6th. Finally, Leerink Swann restated an “outperform” rating and set a $110.00 price objective (up from $105.00) on shares of Nevro Corp. in a research note on Tuesday, November 7th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $100.00.
TRADEMARK VIOLATION WARNING: “Nevro Corp. (NVRO) Position Cut by American Century Companies Inc.” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://sportsperspectives.com/2017/11/24/nevro-corp-nvro-position-cut-by-american-century-companies-inc.html.
Shares of Nevro Corp. (NVRO) traded up $1.23 during trading hours on Friday, reaching $78.06. The company had a trading volume of 387,300 shares, compared to its average volume of 511,112. Nevro Corp. has a 12 month low of $65.82 and a 12 month high of $99.63. The company has a current ratio of 8.78, a quick ratio of 6.81 and a debt-to-equity ratio of 0.59.
Nevro Corp. (NYSE:NVRO) last announced its quarterly earnings data on Monday, November 6th. The medical equipment provider reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. The business had revenue of $82.26 million for the quarter, compared to analyst estimates of $80.50 million. Nevro Corp. had a negative return on equity of 17.27% and a negative net margin of 14.09%. The company’s revenue was up 35.0% on a year-over-year basis. During the same period in the prior year, the company earned ($0.14) earnings per share. research analysts expect that Nevro Corp. will post -1.27 EPS for the current fiscal year.
Nevro Corp. Company Profile
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp. (NYSE:NVRO).
Receive News & Ratings for Nevro Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro Corp. and related companies with MarketBeat.com's FREE daily email newsletter.